⚠ Evidence warning: Clinical trials or other evidence do not support the claim that cat's claw helps chronic fatigue syndrome (ME/CFS), chronic Epstein-Barr virus, HHV-6 or herpes simplex virus infection and Lyme disease, or that it gives broad-spectrum resistance to infection. This page keeps it as a report of what people, websites or other media say.
Cat's Claw for Immune Modulation
Cat's Claw (Uncaria tomentosa) is one of the most thoroughly studied plant immunomodulators in the Western herbal pharmacopeia — and its two alkaloid chemotypes work against each other in laboratory tests. The pentacyclic oxindole alkaloid (POA) fraction (isopteropodine, pteropodine, mitraphylline, uncarine F) was reported in 1985 laboratory work to stimulate phagocytosis (the engulfing of germs by white blood cells); in later laboratory work it made human blood-vessel cells release a factor that increased lymphocyte multiplication; and it is credited with T-cell and natural killer-cell effects. The tetracyclic oxindole alkaloid (TOA) fraction reduced that blood-vessel-cell effect in a dose-dependent way. The small human studies, by contrast, mostly used C-Med-100, a hot-water extract that is almost free of alkaloids (under 0.05%), whose active ingredients were identified as quinic acid esters; the longer-lived white cells were seen in mice given that extract. A bottle labeled simply "Cat's Claw" without chemotype certification is a coin-flip as to which alkaloid chemotype it contains. This deep-dive walks through each immune mechanism, the standardized extracts that drive the clinical evidence, the practical autoimmune and immunosuppressant safety boundaries, and the rationale for the C-Med-100 dosing range used in human trials.
Table of Contents
- Why the POA Chemotype Matters More Than the Dose
- The Pentacyclic Oxindole Alkaloids in Detail
- Phagocytosis Enhancement in Laboratory Studies
- C-Med-100 — The Standardized Hot-Water Extract
- T-Cell and Natural Killer-Cell Support
- Cytokine Modulation and Complement Activation
- Leukocyte Lifespan Extension via Reduced Apoptosis
- DNA Repair Enhancement and Why It Matters for Immune Cells
- Clinical Applications and Dosing
- Safety Boundaries (Autoimmunity & Immunosuppression)
- Key Research Papers
- Connections
- Featured Videos
Why the POA Chemotype Matters More Than the Dose
The single most important practical fact about Cat's Claw is one that most retail consumers never learn. The species Uncaria tomentosa grows wild throughout the Peruvian Amazon as two visually indistinguishable populations with opposite immune pharmacology. The Austrian researcher Klaus Keplinger discovered the chemotype split in the 1970s while working to isolate the active alkaloids from bark samples that produced inconsistent results in his pharmacological assays. He eventually established that what looked like a single species was actually two metabolic populations: one producing pentacyclic oxindole alkaloids (POA), the other producing tetracyclic oxindole alkaloids (TOA).
The pentacyclic alkaloids — five-ring structures including isopteropodine, pteropodine, mitraphylline, speciophylline, isomitraphylline, and uncarine F — are the immunomodulatory fraction. The tetracyclic alkaloids — four-ring structures, primarily rhynchophylline and isorhynchophylline — have their own pharmacology, with effects on the central nervous system and the cardiovascular system, but they are not what consumers seeking an immune supplement are trying to buy.
The critical discovery, made jointly by Keplinger and Laus and published in the Journal of Ethnopharmacology in 1999, is that the two alkaloid classes do not merely have different effects — they actively antagonize each other. In laboratory tests, pentacyclic alkaloids made human endothelial cells (the cells lining blood vessels) release a factor that increased the multiplication of human B and T lymphocytes, and tetracyclic alkaloids reduced this pentacyclic effect in a dose-dependent way (Wurm 1998; Keplinger 1999). These are cell-culture results; the papers’ abstracts do not give a percentage loss of activity for a given amount of TOA.
Roughly half of wild Uncaria tomentosa bark harvests are predominantly TOA chemotype. Mixed harvests are common. Without laboratory chromatographic verification, a consumer buying generic Cat's Claw capsules cannot tell which chemotype the product contains.
Practitioners who focus on the chemotype favor products labeled POA-standardized or TOA-free, and commercial TOA-free extracts are sold for this reason. C-Med-100, the patented hot-water extract used in the Sheng and Pero studies, is a different kind of product: it contains almost no alkaloids of either type. In the practitioners' view, price, brand reputation and organic certification do not address the underlying chemotype question.
The Pentacyclic Oxindole Alkaloids in Detail
Within the POA fraction, the most pharmacologically active individual alkaloids are isopteropodine, pteropodine, mitraphylline, speciophylline, isomitraphylline, and uncarine F. Of these, isopteropodine is generally the most abundant in POA-chemotype bark and is the alkaloid most strongly associated with phagocytosis enhancement.
- Isopteropodine is the dominant alkaloid in most POA harvests and the lead immunostimulant. Laboratory work from 1985 reported a phagocytosis-stimulating action for the cat's claw alkaloids (Wagner 1985). It binds (with low affinity) to muscarinic and 5-HT receptors, which may contribute to additional central nervous system (CNS) effects, but its primary immune action appears to be on innate immune cells.
- Pteropodine is structurally similar to isopteropodine and shares the immunomodulatory profile. It has been characterized as having moderate affinity for 5-HT receptors and may contribute to the modest mood-stabilizing effects some users report.
- Mitraphylline has anti-inflammatory, muscle-relaxant, and diuretic activity in addition to its immune effects. It has been investigated for anti-tumor activity in cell-culture models against Ewing sarcoma and breast cancer cell lines, though clinical translation remains very early.
- Speciophylline and isomitraphylline are lower-abundance pentacyclic alkaloids that contribute to the overall POA activity. Their individual pharmacology is less characterized than the lead three.
- Uncarine F is associated specifically with enhancement of lymphocyte proliferation in response to mitogens — a marker of adaptive immune capacity. It is often included as one of the alkaloids quantified in chemotype certification panels.
POA-standardized extracts typically specify total POA content as a percentage of dry bark mass (commonly 1.3% to 3%) and list individual alkaloid percentages in the certificate of analysis. The total pentacyclic alkaloid load delivered per capsule, not the headline bark mass, is the relevant dosing parameter.
Phagocytosis Enhancement in Laboratory Studies
Phagocytosis is the process by which neutrophils, macrophages, and other "professional phagocytes" engulf and destroy bacteria, viruses, cellular debris, and apoptotic cells. It is the workhorse mechanism of innate immunity and the foundation on which adaptive immunity is layered. A higher phagocytic index means immune cells are more efficient per encounter at identifying and clearing pathogens.
The phagocytic-enhancement effect of Cat's Claw was first characterized by Wagner and colleagues in the 1980s using granulocyte cultures from human donors (Wagner 1985, published in German). Later work by Wurm et al. (Planta Medica 1998) did not measure phagocytosis: it found that pentacyclic alkaloids made human endothelial cells release a still-unidentified factor that significantly increased the multiplication of resting or weakly activated human B and T lymphocytes in the laboratory, while tetracyclic alkaloids reduced this effect.
Importantly, this enhancement is not produced by isolated alkaloids alone — whole-bark POA extracts outperform purified pentacyclic alkaloid concentrates. The effect appears to require the triterpene and glycoside fractions present in whole-plant extracts as well, suggesting either synergy among multiple compound classes or a requirement for the broader chemical matrix to deliver the alkaloids to their target cells.
The clinical translation: in a healthy adult population, baseline phagocytosis is generally adequate, and the effect of supplementation may not be noticeable. The relevant clinical contexts are those where phagocytic function is suppressed — aging (immunosenescence), chronic illness, post-chemotherapy recovery, recurrent low-grade infections, and chronic stress with elevated cortisol. In these contexts, POA-driven phagocytic enhancement may restore innate immune function toward baseline.
C-Med-100 — The Standardized Hot-Water Extract
C-Med-100 is a proprietary water-soluble extract of Uncaria tomentosa bark developed by Pero and Bryngelsson in the 1990s and used in most of the clinical research on Cat's Claw published from the late 1990s onward. The extract is produced by a hot-water extraction process that preserves the carboxy alkyl ester fraction (CAEs) and removes the alkaloid fraction almost entirely — a counterintuitive design that emerged from the observation that the water-soluble fraction retained the DNA-repair and immune-enhancing activity while shedding the alkaloid-related central nervous system effects.
This means there are two different kinds of cat's claw research. The work on the pentacyclic (POA) alkaloids is mostly laboratory cell-culture work. The C-Med-100 human studies used a hot-water extract containing under 0.05% alkaloids, and a 2005 study by the same group identified its active ingredients as quinic acid esters (Sheng 2005). So the human results come from an almost alkaloid-free extract and cannot be credited to the POA chemotype.
The Sheng, Bryngelsson, and Pero study published in the Journal of Ethnopharmacology in 2000 was mostly an animal study. Female rats were given C-Med-100 by mouth every day at 5–80 mg/kg for 8 weeks; a small human part gave four healthy adult men 5 mg/kg a day for 6 weeks. Key findings:
- In rats, white blood cell counts rose significantly at 40 and 80 mg/kg for 8 weeks (and at 160 mg/kg for 4 weeks), and spleen lymphocytes multiplied more strongly when stimulated with phytohemagglutinin (PHA)
- In the four men, white blood cell counts rose significantly after supplementation, and no toxicity was seen
- In rats, repair of DNA single-strand and double-strand breaks 3 hours after whole-body irradiation was significantly improved
- No acute or chronic toxicity was seen in the rats, and the single oral dose that kills half of rats (LD50) was above 8 g/kg
A 2001 study by the same group tested 250 mg and 350 mg a day for 8 weeks in 12 healthy adults (see the DNA repair section).
In a study of male volunteers at a general practice in New York City, men who took C-Med-100 (350 mg twice a day for two months) were compared with untreated men after a 23-valent pneumococcal vaccine. The supplemented men had a higher lymphocyte-to-neutrophil ratio in their blood and lost antibody to the 12 vaccine serotypes measured more slowly over 5 months. No toxic side effects were seen on medical examination, blood chemistry or blood counts (Lamm 2001).
A 2012 randomized trial in Brazil studied patients with Stage II invasive ductal breast cancer on FAC chemotherapy (fluorouracil, doxorubicin, cyclophosphamide). One group took 300 mg of dry cat's claw extract a day with chemotherapy; the other had chemotherapy alone, with no placebo. The cat's claw group had less chemotherapy-induced neutropenia (low neutrophil counts), and the authors wrote that the extract “was also able to restore cellular DNA damage” (Santos Araújo 2012). The trial's abstract describes a dry cat's claw extract and does not name C-Med-100. Earlier, a rat study by Sheng, Pero and Wagner (2000) found that rats given C-Med-100 after doxorubicin recovered their white blood cell counts sooner than untreated rats.
C-Med-100 doses in the published human studies range from 250 to 700 mg/day (the 700 mg given as 350 mg twice a day). This is substantially lower than the bulk-bark capsule dosing (1,000–3,000 mg/day) described for non-standardized preparations — reflecting the higher activity-per-milligram of the standardized extract.
T-Cell and Natural Killer-Cell Support
Beyond innate immunity, Cat's Claw POA extracts have measurable effects on the adaptive immune system, particularly on T-lymphocytes and natural killer (NK) cells. The effects are best characterized as immune-modulating rather than purely immune-stimulating — the extracts appear to push function toward baseline in contexts of underactivity without producing pathological hyperstimulation.
T-cell effects documented in the literature:
- Increased lymphocyte proliferation in response to standard mitogens (phytohemagglutinin, concanavalin A) in cultures of peripheral blood mononuclear cells from supplemented donors. The proliferation index measures the capacity of T cells to mount an antigen response when called upon.
- Cytotoxic T-cell (CD8+) activity against virally infected target cells is enhanced in POA-exposed cultures, suggesting improved capacity for virally-induced cell killing.
- Helper T-cell (CD4+) cytokine output shifts toward a balanced Th1/Th2 profile, which is the desired pattern for general immune competence (heavily skewed Th1 or Th2 patterns are associated with autoimmunity and allergy respectively).
Natural killer-cell effects:
- Natural killer-cell cytotoxicity against tumor cell line targets (K562) is enhanced in POA-exposed cultures, with effect sizes of 20–40% above baseline at therapeutic concentrations.
- Natural killer-cell activation markers (CD69, CD107a) show modest upregulation, consistent with a true functional enhancement rather than purely an increase in cell numbers.
These effects are mechanistically consistent with the observed clinical benefits in chemotherapy-induced immunosuppression, in chronic viral infection management, and in the integrative oncology applications where Cat's Claw is used as an adjunct to conventional cancer therapy.
Cytokine Modulation and Complement Activation
Cat's Claw exhibits a sophisticated cytokine-modulating profile that distinguishes it from blunt immune stimulants. The pattern is one of context-dependent modulation: pro-inflammatory cytokine production is enhanced when a true pathogen-driven immune response is needed, but excessive or chronic inflammatory cytokine output is suppressed via the NF-kB inhibitory mechanism.
Key cytokine findings:
- Interleukin-1 (IL-1) and interleukin-6 (IL-6) production by activated monocytes is enhanced in response to bacterial lipopolysaccharide (LPS) challenge in POA-exposed cells, supporting an effective acute-phase response.
- Tumor necrosis factor-alpha production is paradoxically reduced in the context of chronic low-grade inflammation but is not blunted in the context of acute pathogen challenge — reflecting the NF-kB modulation discussed in the anti-inflammatory deep-dive.
- Interferon-gamma output by natural killer cells is enhanced, supporting both antiviral defense and the Th1 axis of cellular immunity.
The complement system — a cascade of approximately 30 plasma proteins that amplify innate immune responses through opsonization (marking pathogens for destruction), membrane attack complex formation (directly lysing bacterial cells), and inflammatory signaling — is also enhanced by Cat's Claw POA extracts. Specifically, the classical and alternative complement pathways show modestly elevated activity in supplemented animals and in cell-culture models. This enhances the efficiency of antibody-mediated pathogen clearance and is one of the mechanisms behind the broad-spectrum infection-resistance effects observed in traditional use.
Leukocyte Lifespan Extension via Reduced Apoptosis
One of the more distinctive properties reported for Cat's Claw, and one not widely shared by other immune-modulating herbs, is longer survival of white blood cells (less programmed cell death, or apoptosis). The evidence comes from mice, and from the almost alkaloid-free C-Med-100 water extract rather than from POA extracts. Mice given C-Med-100 in their drinking water had more spleen cells, rising with the dose, because the cells survived longer rather than because more were made; the proportions of the different white-cell types stayed normal, and spleen cell numbers returned to normal within four weeks of stopping (Akesson 2003).
The clinical implication of this finding is that Cat's Claw supplementation may effectively increase the population of functional immune cells available to mount responses without changing the rate at which they are produced — longer-lived leukocytes mean more cells in circulation at any given time. This is mechanistically distinct from bone-marrow stimulation (which increases production) and from peripheral immune activation (which enhances per-cell function). The combination of all three effects in a single botanical is part of what makes Cat's Claw distinctive in the immune-herb pharmacopeia.
The implications are largest in populations where accelerated leukocyte apoptosis contributes to immune dysfunction:
- Elderly patients with immunosenescence, where increased leukocyte apoptosis is a recognized mechanism of declining infection resistance with age
- Post-chemotherapy recovery, where cytotoxic drugs have accelerated leukocyte loss
- Chronic stress states with elevated cortisol, where stress-induced lymphocyte apoptosis is well-documented
- Chronic viral infection states (chronic Epstein-Barr virus (EBV) reactivation, chronic HHV-6, chronic HSV) where viral mechanisms accelerate immune-cell death
DNA Repair Enhancement and Why It Matters for Immune Cells
The Sheng et al. work on C-Med-100 also documented a distinctive effect not seen in most immune herbs: enhanced DNA repair capacity in peripheral blood lymphocytes. After eight weeks of supplementation, donor lymphocytes showed reduced DNA damage after ex-vivo hydrogen peroxide challenge, indicating improved capacity for both base excision repair (BER) and nucleotide excision repair (NER) pathways.
The human source for this is a 2001 study of 12 healthy adults who worked in the same environment. Two groups took 250 mg or 350 mg of the C-Med-100 water extract daily for 8 weeks, and a third group took nothing. After a standard hydrogen-peroxide challenge, blood cells from the supplemented groups showed significantly less DNA damage and more DNA repair than those of the controls, with no toxic effects on symptoms, blood chemistry or blood counts (Sheng 2001). The earlier evidence came from rats, whose repair of DNA breaks after whole-body irradiation improved on C-Med-100 (Sheng 2000).
This matters for immune function because lymphocytes undergo rapid clonal expansion when mounting antigen responses — a single antigen-specific T cell may divide 15–20 times in the days following activation, producing 10,000+ daughter cells. Each division requires error-free DNA replication and rapid repair of any spontaneous damage. Cells with impaired DNA repair capacity proliferate poorly, undergo replication-associated apoptosis, or accumulate mutations that compromise function.
By enhancing DNA repair, the C-Med-100 water extract is proposed to help lymphocytes maintain genomic integrity during the rapid proliferation required for effective adaptive immune responses — producing more functional effector T cells and antibody-secreting B cells per antigen encounter. This is a quiet but consequential mechanism, and one that distinguishes Cat's Claw from echinacea, astragalus, and other immune herbs whose mechanisms operate at the surface receptor or cytokine level rather than at the nucleic acid level.
The same DNA-repair enhancement is the mechanistic basis for the integrative-oncology interest in Cat's Claw as an adjunct during and after chemotherapy — cytotoxic drugs work largely through DNA damage, and the speed and fidelity of host DNA repair in non-cancer tissues determines much of the side-effect profile.
Clinical Applications and Dosing
The uses described for Cat's Claw extracts for immune modulation cluster around four contexts:
- Recurrent low-grade infection susceptibility in adults — the most common indication for over-the-counter use. Doses described in practice: 250–350 mg of C-Med-100 once daily for 8–12 weeks, then a 2–4 week break; bulk POA-standardized bark capsules at 500–1000 mg two to three times daily. The published C-Med-100 human studies used 250–700 mg a day for up to two months.
- Adjunctive immune support during and after chemotherapy — based on the Brazilian breast-cancer trial (300 mg of dry cat's claw extract a day alongside FAC chemotherapy) and the rat leukopenia study of C-Med-100. Practitioners describe C-Med-100 at 350 mg daily. Cat's Claw is reported to weakly inhibit cytochrome P450 3A4 (CYP3A4), the liver enzyme that breaks down many drugs (see Drug interactions below).
- Chronic fatigue and post-viral syndromes — including chronic Epstein-Barr reactivation and the chronic immune-dysregulation states often grouped under "myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)." Practitioners describe the same 250–350 mg daily C-Med-100 dose, often combined with other immune-supporting herbs such as astragalus and reishi.
- Integrative Lyme protocols — detailed in the Lyme-disease deep-dive. A commercial TOA-free extract is used in the Cowden protocol at protocol-specific dosing (typically titrated upward over several weeks).
Practitioners who favor POA-standardized products hold that, for all uses, the chemotype-certification question outweighs the dosing question — that the highest dose of a TOA-contaminated product delivers less activity than a moderate dose of a POA-standardized product.
Time to observed effect varies by indication. Clinical trials have generally shown measurable laboratory effects (WBC count, phagocytic index) within 4 weeks and clinical effects (symptom improvement in inflammatory conditions) within 6–12 weeks. Cat's Claw is not an acute-illness remedy — it works through sustained modulation of immune function and requires consistent dosing over weeks.
Safety Boundaries (Autoimmunity & Immunosuppression)
The same broad immune-activating profile that makes Cat's Claw useful for the indications above is the basis for the safety concerns raised for the groups below.
- Organ-transplant recipients on immunosuppressant therapy — STRICT CONTRAINDICATION. Cat's Claw is strictly contraindicated for patients taking cyclosporine, tacrolimus, sirolimus, mycophenolate, or other immunosuppressant drugs after solid-organ transplantation. The concern rests on the herb's reported immune-activating effects, which could work against these drugs and trigger acute rejection.
- Active autoimmune disease — a mixed picture. Paradoxically, some autoimmune conditions (rheumatoid arthritis specifically, where the Mur trial showed benefit) may improve on Cat's Claw due to its NF-kB and tumor necrosis factor-alpha modulating effects. Others (lupus, Hashimoto's, multiple sclerosis) may worsen because of immune-activating effects. Because the herb is reported to stimulate parts of the immune system, the research raises a concern for people with autoimmune conditions other than rheumatoid arthritis.
- Pregnancy — a traditional contraceptive and abortifacient. Cat's Claw has traditional use as a contraceptive and abortifacient among Amazonian indigenous groups. Modern supplement doses are far lower than traditional preparations, but there is no good safety data on their use in pregnancy.
- Breastfeeding — there is no safety data on whether its alkaloids pass into breast milk.
- Pre-surgical period — Cat's Claw is reported to have mild antiplatelet effects that could increase bleeding risk during surgery; practitioners describe stopping it 2–3 weeks before scheduled surgery.
- Drug interactions — in addition to the immunosuppressant interaction above, Cat's Claw may interact with anticoagulants (warfarin, heparin, apixaban, rivaroxaban), antiplatelet drugs (clopidogrel, aspirin), and antihypertensives. With blood thinners and antiplatelet drugs, the concern is added bleeding risk from its reported antiplatelet effect. Cat's Claw is also a weak inhibitor of cytochrome P450 3A4 (CYP3A4), which may modestly affect plasma levels of drugs metabolized by that enzyme (statins, calcium channel blockers, some immunosuppressants).
For more on the broader immune-related and inflammatory applications and the safety overlap with conventional anti-inflammatory therapy, see the anti-inflammatory deep-dive and the rheumatoid arthritis trial summary.
Key Research Papers
- Wurm M, Kacani L, Laus G, Keplinger K, Dierich MP (1998). Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. Planta Medica 64(8): 701–704. — PubMed PMID: 9933988
- Sheng Y, Bryngelsson C, Pero RW (2000). Enhanced DNA repair, immune function and reduced toxicity of C-MED-100, a novel aqueous extract from Uncaria tomentosa. Journal of Ethnopharmacology 69(2): 115–126. — PubMed PMID: 10687868
- Sheng Y, Pero RW, Wagner H (2000). Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine 7(2): 137–143. — PubMed PMID: 10839217
- Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H (1999). Uncaria tomentosa (Willd.) DC. — ethnomedicinal use and new pharmacological, toxicological and botanical results (POA/TOA antagonism). Journal of Ethnopharmacology 64(1): 23–34. — PubMed PMID: 10075119
- Lemaire I, Assinewe V, Cano P, Awang DV, Arnason JT (1999). Stimulation of interleukin-1 and -6 production in alveolar macrophages by the neotropical liana Uncaria tomentosa (uña de gato). Journal of Ethnopharmacology 64(2): 109–115. — PubMed PMID: 10197746
- Aguilar JL, Rojas P, Marcelo A, et al. (2002). Anti-inflammatory activity of two different extracts of Uncaria tomentosa. Journal of Ethnopharmacology 81(2): 271–276. — PubMed PMID: 12065162
- Akesson C, Pero RW, Ivars F (2003). C-Med 100, a hot water extract of Uncaria tomentosa, prolongs lymphocyte survival in vivo. Phytomedicine 10(1): 23–33. — PubMed PMID: 12622460
- Akesson C, Lindgren H, Pero RW, et al. (2003). An extract of Uncaria tomentosa inhibiting cell division and NF-kappaB activity without inducing cell death. International Immunopharmacology 3(13–14): 1889–1900. — PubMed PMID: 14636838
- Heitzman ME, Neto CC, Winiarz E, Vaisberg AJ, Hammond GB (2005). Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry 66(1): 5–29. — PubMed PMID: 15649507
- Domingues A, Sartori A, Golim MA, et al. (2011). Prevention of experimental diabetes by Uncaria tomentosa extract: Th2 polarization, regulatory T cell preservation or both? Journal of Ethnopharmacology 137(1): 635–642. — PubMed PMID: 21718770
- Reinhard KH (1999). Uncaria tomentosa (Willd.) D.C.: cat's claw, uña de gato, or saventaro. Journal of Alternative and Complementary Medicine 5(2): 143–151. — PubMed PMID: 10328636
- Wagner H, Kreutzkamp B, Jurcic K (1985). [The alkaloids of Uncaria tomentosa and their phagocytosis-stimulating action] (article in German). Planta Medica (5): 419–423. — PubMed PMID: 4080851
- Sheng Y, Li L, Holmgren K, Pero RW (2001). DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study. Phytomedicine 8(4): 275–282. — PubMed PMID: 11515717
- Lamm S, Sheng Y, Pero RW (2001). Persistent response to pneumococcal vaccine in individuals supplemented with a novel water soluble extract of Uncaria tomentosa, C-Med-100. Phytomedicine 8(4): 267–274. — PubMed PMID: 11515716
- Sheng Y, Akesson C, Holmgren K, Bryngelsson C, Giamapa V, Pero RW (2005). An active ingredient of Cat's Claw water extracts identification and efficacy of quinic acid. Journal of Ethnopharmacology 96(3): 577–584. — PubMed PMID: 15619581
- Santos Araújo Mdo C, Farias IL, Gutierres J, et al. (2012). Uncaria tomentosa — Adjuvant Treatment for Breast Cancer: Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2012: 676984. — PubMed PMID: 22811748
- Allen-Hall L, Cano P, Arnason JT, et al. (2007). Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression if IL-1beta and TNF-alpha. Journal of Ethnopharmacology 109(2): 312–317. — PubMed PMID: 16959454
PubMed Topic Searches
Connections
- All Herbs
- Cat's Claw Overview
- Cat's Claw Benefits Hub
- Cat's Claw for Rheumatoid Arthritis
- Cat's Claw Anti-Inflammatory (NF-kB)
- Cat's Claw for Lyme Disease
- Astragalus (Long-Term Immune Tonic)
- Echinacea (Acute Immune Activation)
- Andrographis
- Turmeric (Curcumin, NF-kB)
- Immune Boosting
- Lyme Disease
- Cancer (Adjunctive Use)
- Vitamin D3 (Immune Cofactor)
- Zinc (Immune Cofactor)
- History